British biotech firm secures coveted FDA designation in bid to develop world's first treatment for rare, incurable and deadly disease
A leading UK biotech firm founded to develop the world’s first treatment for a rare, incurable and deadly disease has secured its first Food and Drug Administration (FDA) designation. SynaptixBio, which aims to tackle TUBB4a leukodystrophy – a genetic and debilitating condition which mainly affects babies and ...
Source: pharmiweb.com
